Management of Hepatolithiasis: Review of the Literature

By -

 



Executive Summary

Hepatolithiasis is a complex disease characterized by the formation of stones within the intrahepatic bile ducts. Historically endemic to Southeast Asia, the disease is seeing increased prevalence in Western nations due to immigration and shifts in global dietary patterns. The pathogenesis is multifactorial, involving genetic bile metabolic defects, bacterial infection, and anatomical abnormalities.

Management requires a multidisciplinary approach, as the disease is associated with high recurrence rates and severe long-term complications, most notably biliary cirrhosis and cholangiocarcinoma. While non-surgical interventions like endoscopic and percutaneous lithotomy provide less invasive options for stone clearance, partial hepatectomy remains the definitive treatment for localized disease, offering the lowest recurrence rates. For terminal cases with diffuse involvement or liver failure, liver transplantation serves as a final, though resource-limited, therapeutic option.

Epidemiology and Clinical Presentation

Hepatolithiasis typically manifests between the third and seventh decades of life, peaking in the 50s and 60s. It affects men and women almost equally.

Geographic Distribution and Dietary Shifts

  • Southeast Asia: The disease remains most prevalent in this region; in Taiwan, it accounts for up to 53.5% of all biliary stone presentations.

  • Western Trends: Prevalence in the West now likely exceeds the historical estimate of 1% of biliary stone cases.

  • Dietary Impact: A 25-year survey in Japan showed a decline in prevalence (4.1% to 1.7%) as the population adopted a Westernized diet. Conversely, high-fat, high-protein diets correlate with increased gallbladder stones, which is a distinct pathology.

Clinical Manifestations

  • Charcot’s Triad: Characterized by abdominal pain, fever, and jaundice.

  • Reynold’s Pentad: Includes the triad plus confusion and hypotension; this indicates a poor prognosis and potential progression to life-threatening sepsis or liver abscesses.

  • Anatomical Distribution: The left hepatic duct is involved in up to 78% of cases, with unilateral left-sided disease occurring in 33–50% of patients.

Etiology and Pathogenesis

The formation of intrahepatic stones is driven by four primary factors: bile metabolic defects, infection, anatomical abnormalities, and cholestasis.

Stone Composition

Approximately 90% of intrahepatic stones are soft, friable, brown-pigmented calcium bilirubinate stones. These differ from gallbladder stones, which are primarily composed of cholesterol.

Pathogenic Factors

  • Genetic Defects: Mutations in the ABCB11 gene (encoding the bile salt export pump) and ABCB4 (encoding multidrug resistance protein 3) reduce bile acid secretion, facilitating stone formation.

  • Bacterial Influence: Bacteria produce beta-glucuronidase, which hydrolyzes bile, allowing it to combine with calcium to form deposits. Bacterial activity also increases intraductal pH and stimulates mucin production, creating an environment conducive to lithogenesis.

  • Anatomical Abnormalities: Native or acquired strictures (from Caroli’s syndrome, surgery, or primary sclerosing cholangitis) lead to bile stasis. The left hepatic duct is particularly susceptible because it meets the common hepatic duct at a near right angle.

  • Proliferative Cholangitis: Found in ~75% of Asian cases, chronic inflammation leads to epithelial hyperplasia and mucin secretion, further stimulating stone formation.

Non-Surgical Management Modalities

Pharmacologic Options

Current medical therapies focus on increasing bile flow and reducing inflammation, though many are supportive or experimental.

  • Ursodeoxycholate (UDC): Promotes membrane-protective effects and may induce stone resolution or prevent recurrence.

  • Homeopathic Remedies: Inchinkoto (ICKT), a plant-based remedy used in Asia, stimulates bile formation.

  • Experimental Targets: COX-2 inhibitors, PGE antagonists, and EGF inhibitors (like panitumumab) are being researched to inhibit biliary hyperplasia.

Procedural Interventions

Procedural management aims for stone removal through lithotomy (extraction) or lithotripsy (fragmentation).

  • Endoscopic (POCSL): Uses peroral cholangioscopy. It offers a low complication rate but often requires multiple attempts for clearance.

  • Percutaneous (PTCSL): Preferred for patients with high surgical risk or complex stone distributions. While effective for clearance (up to 85%), it carries risks of liver laceration and major vascular disruption.

  • Lithotripsy: Laser lithotripsy (PTBLL) is the most effective for larger stones in difficult locations, while electrohydraulic lithotripsy (EHL) is a more affordable but potentially more damaging alternative.

Surgical Management

Surgery is considered the definitive treatment for selected patients, particularly those with localized disease or suspected malignancy.

Partial Hepatectomy

  • Indications: Unilobar disease (especially left-sided), severe fibrosis/atrophy of liver segments, liver abscesses, or suspected cholangiocarcinoma.

  • Outcomes: Open partial hepatectomy achieves final stone clearance rates of 81.7–99.3%. It offers higher survival and lower recurrence rates compared to non-surgical methods.

  • Laparoscopic Approach: An emerging alternative with comparable clearance rates (~95%) and significantly lower intraoperative blood loss and shorter hospital stays.

Liver Transplantation

Reserved for terminal, incurable hepatolithiasis characterized by:

  • Diffuse bilateral stones and strictures.

  • End-stage decompensated cirrhosis.

  • Malignancy (cholangiocarcinoma).

  • Failure of multiple prior operations.

While effective, transplantation is limited by organ scarcity and high complication rates (6–34%). A specific post-transplant risk is Biliary Cast Syndrome (BCS), which mimics hepatolithiasis and occurs in 3–25% of transplanted livers.

Prognosis and Long-Term Complications

Hepatolithiasis significantly increases all-cause mortality, particularly when diagnosis is delayed or complications arise.

  • Survival Rates: The 10-year survival rate is 92.7% in the absence of major complications but drops to 42.7% if cirrhosis or cholangiocarcinoma develops.

  • Biliary Cirrhosis: Develops in 6.0–7.4% of patients.

  • Cholangiocarcinoma: This is the most feared complication, with a conversion rate of 2.4–13.0%. It is driven by a metaplasia-dysplasia-carcinoma sequence caused by chronic inflammation.

  • Surveillance: For patients with recurrent stones, CT scans (92.9% diagnostic rate) and MRCP (88.5%) are preferred over ultrasonography for detecting early-stage malignancy. CA19-9 and CEA markers are valuable for monitoring but not recommended for primary screening.